Journal
ACS SYNTHETIC BIOLOGY
Volume 10, Issue 5, Pages 1095-1105Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acssynbio.0c00612
Keywords
synthetic circuit; RNA binding protein; MYC; WNT; CRC
Categories
Funding
- National Natural Science Foundation of China [82003254]
Ask authors/readers for more resources
The challenge in colorectal cancer treatment is the lack of specific-targeting therapy to precisely kill malignant cells. A study designed an RNA-only delivery kill switch to eliminate CMS2 type CRC cells, showing a proof-of-principle approach for targeted therapy.
The lack of specific-targeting therapy to precisely identify and kill malignant cells while sparing others is a great challenge in colorectal cancer (CRC) treatment. In the era of molecular classification of tumors, CRC has been grouped into four Consensus Molecular Subtypes. Accounting for 37% of all types, the CMS2 group (canonical type) shows distinguishing features: WNT and MYC signaling activation. In this study, we designed an RNA-only delivery kill switch to specifically eliminate CMS2 type CRC cells. The sensing and logic processing functions are integrated by the newly engineered L7Ae, which can not only detect the stability of beta-catenin protein and the presence of cytoplasm located Myc/Myc-nick, but also do logic computation. The circuit specifically eliminated HCT-116 cells while sparing other kinds of cells, showing a proof-of-principle approach to precisely target CMS2 type CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available